Clinical Trials & Research

About our Clinical Trials

Dana-Farber/Children's Hospital Cancer Center is one of the top pediatric research centers in the world, and our scientific advances are propelled by our unique clinical trials. We offer an average of 60 different trials—all with the aim of improving care for children with cancer and blood diseases.

Researcher

In addition:

  • we are the only pediatric program in New England offering enrollment on Children's Oncology Group Phase I studies.
  • we participate and hold leadership positions in several national cooperative research groups.
  • our studies have built the foundation for new and improved cancer and blood disease therapies.

Find a trial

Search current pediatric cancer and blood disease-related clinical trials offered through Dana-Farber and Children's Hospital Boston:

• Blood-Related • Neuroblastoma
• Brain Tumor • Non-Hodgkin Lymphoma
• Hodgkin Lymphoma • Oncology
• Kidney Tumor • Sarcoma
• Leukemia • Solid Tumor
• Lymphoma • Wilms Tumor

For more information on our clinical trials, please email dfchcc_clinicaltrials@dfci.harvard.edu.

Research and Innovation

Our research efforts cover the full spectrum of cancer
and blood diseases, including the most rare and complex conditions. From refining current approaches to making transformative discoveries, we are working every day on innovations to
change – and save – children's lives.

Read about some of our recent breakthroughs:

Sickle Cell Disease and the Thalassemias: The Advantages of Staying Forever Young
Flipping a single molecular switch could turn off the mutation that causes sickle cell disease: Dr. Stuart Orkin has already done it in mice.

Getting to the Root of a Hard-to-Treat Childhood Leukemia
Dr. Scott Armstrong and his colleagues may have found the key to fighting an especially challenging segment of acute leukemias.

A New Start for Gene Therapy for 'Bubble Boy' Disease
Baby Agustín has a form of X-linked Severe Combined Immunodeficiency (SCID-X1), better known as “bubble boy” disease. But, in an incredible development, his T-cell function has tested normal after his participation in a gene therapy trial at DF/CHCC'.